Approval · Notice of Compliance 19840 · 2017
LANVIS: Notice of Compliance 19840
Issued September 21, 2017
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 19840
- Date
- September 21, 2017
- Company
- Aspen Pharmacare Canada Inc.Oakville, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To update the product mnograph with safety and pharmacokinetic information and to remove the following indication: lanvis has also been used in chronic granulocytic (myolocytic, myeloid, myelogenous) leukemia
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| LANVIS | Not yet assigned | — |
Medicinal ingredients
- THIOGUANINE 40 MG per TAB